{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:01Z","timestamp":1792636861667,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA180984"],"award-info":[{"award-number":["CA180984"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA275993"],"award-info":[{"award-number":["CA275993"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA279746"],"award-info":[{"award-number":["CA279746"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A paradigm shift in advanced prostate cancer toward the use of oral specialty drugs has been accompanied by increased involvement of urologists. In fact, some urology groups can deliver these medications in the office, providing them directly to their patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was performed using a 20% national sample of men with advanced prostate cancer enrolled in Traditional Medicare and managed by independent urology groups between 2011 and 2019. Urology groups with and without in\u2010office dispensing were identified. Multivariable logistic regression was used to assess relationships between urology group characteristics and in\u2010office dispensing. A difference\u2010in\u2010differences design was used to measure the effect of in\u2010office dispensing on the use of oral specialty drugs within urology group markets compared to markets without dispensing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Urology group characteristics associated with adoption of in\u2010office dispensing included large practice size (OR 2.9, 95% CI 1.2\u20136.5), increasing volume of men with advanced prostate cancer (OR 1.1 per 10\u2010patient increase, 95% CI 1.0\u20131.2), decreasing social vulnerability of the group's patient population (OR 0.81 per 0.1 unit increase, 95% CI 0.69\u20130.95), lower competition (OR 1.02 per 100 unit increase in the Herfindahl\u2013Hirschman Index, 95% CI 1.0\u20131.1), and radiation vault ownership (OR 3.1, 95% CI 1.1\u20138.4). Compared with markets of urology groups that did not adopt in\u2010office dispensing, adopting markets experienced a significant increase in oral specialty drug prescriptions (adjusted difference\u2010in\u2010differences estimate, 46 prescriptions per 1000 men,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adoption of in\u2010office dispensing by independent urology groups increased oral specialty drug prescriptions for advanced prostate cancer within a group's market.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71475","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T04:01:49Z","timestamp":1768190509000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of In\u2010Office Dispensing Adoption by Urology Practices on Oral Specialty Drug Use in Advanced Prostate Cancer"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-0446","authenticated-orcid":false,"given":"Kassem S.","family":"Faraj","sequence":"first","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Oerline","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dall","sequence":"additional","affiliation":[{"name":"Department of Urology Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9772-1415","authenticated-orcid":false,"given":"Arnav","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1597-5428","authenticated-orcid":false,"given":"Megan E. V.","family":"Caram","sequence":"additional","affiliation":[{"name":"VA Health Services Research &amp; Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System  Ann Arbor Michigan USA"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahakn B.","family":"Shahinian","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent K.","family":"Hollenbeck","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.23.2.82"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.23.2.70"},{"key":"e_1_2_12_4_1","unstructured":"New Survey Finds Medical Group Operating Costs Continue to Outpace Revenue accessed 21 May 2024 https:\/\/www.amga.org\/about\u2010amga\/amga\u2010newsroom\/press\u2010releases\/12182023\/."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.1372"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.08.001"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2019.07.009"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194951"},{"key":"e_1_2_12_9_1","unstructured":"Prostate Cancer Version 4 (2023) accessed 19 September 2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.56592"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac023"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad062"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3909\/riu0737"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33176"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1090"},{"key":"e_1_2_12_16_1","unstructured":"Spending On Prescription Drugs In The US: Where Does All The Money Go? accessed 21 May 2024 https:\/\/www.healthaffairs.org\/content\/forefront\/spending\u2010prescription\u2010drugs\u2010us\u2010does\u2010all\u2010money\u2010go."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35168"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33864"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac081"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae155"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj230"},{"key":"e_1_2_12_22_1","unstructured":"Medicare Data on Provider Practice and Specialty (MD\u2010PPAS) accessed 6 June 2023 https:\/\/resdac.org\/cms\u2010data\/files\/md\u2010ppas."},{"key":"e_1_2_12_23_1","unstructured":"dataQ \u2013 Home accessed 06 May 2024 https:\/\/dataq.ncpdp.org\/."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00088"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2023.04.022"},{"issue":"3","key":"e_1_2_12_26_1","first-page":"313","article-title":"A Variable\u2010Radius Measure of Local Hospital Market Structure","volume":"28","author":"Phibbs C. S.","year":"1993","journal-title":"Health Services Research"},{"key":"e_1_2_12_27_1","unstructured":"HUD USPS ZIP Code Crosswalk Files accessed 29 May 2023 https:\/\/www.huduser.gov\/portal\/datasets\/usps_crosswalk.html."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16153"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02297"},{"key":"e_1_2_12_30_1","unstructured":"PBM's Attack on Physician Dispensing and Impact on Patient Care accessed 22 May 2024 https:\/\/communityoncology.org\/pbms\u2010attack\u2010on\u2010physician\u2010dispensing\u2010and\u2010impact\u2010on\u2010patient\u2010care\/."},{"key":"e_1_2_12_31_1","unstructured":"\u201cFollow The Money: The Flow Of Funds In The Pharmaceutical Distribution System \u201dHealth Affairs Blog. June 13 2017."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2009.0563"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2589"},{"key":"e_1_2_12_34_1","unstructured":"ZYTIGA (Abiraterone Acetate) accessed 23 March 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202379s035lbl.pdf."},{"key":"e_1_2_12_35_1","unstructured":"XTANDI (Enzalutamide) accessed 24 March 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213674s010 203415s022lbl.pdf."},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000269"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00152"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1077"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010075244"},{"key":"e_1_2_12_40_1","unstructured":"DOES PRIVATE EQUITY INVESTMENT IN HEALTHCARE BENEFIT PATIENTS? EVIDENCE FROM NURSING HOMES accessed 15 June 2023 https:\/\/www.nber.org\/system\/files\/working_papers\/w28474\/w28474.pdf."},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.23147"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9581"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:00:47Z","timestamp":1772967647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cam4.71475"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71475","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71475"}}